AU2019270277B9 - Treatment of cancer - Google Patents

Treatment of cancer Download PDF

Info

Publication number
AU2019270277B9
AU2019270277B9 AU2019270277A AU2019270277A AU2019270277B9 AU 2019270277 B9 AU2019270277 B9 AU 2019270277B9 AU 2019270277 A AU2019270277 A AU 2019270277A AU 2019270277 A AU2019270277 A AU 2019270277A AU 2019270277 B9 AU2019270277 B9 AU 2019270277B9
Authority
AU
Australia
Prior art keywords
ser
val
thr
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019270277A
Other languages
English (en)
Other versions
AU2019270277B2 (en
AU2019270277A1 (en
Inventor
Shaad Essa Abdullah
Ashok Kumar Gupta
Xuyang SONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
MedImmune Ltd
Original Assignee
Innate Pharma SA
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA, MedImmune Ltd filed Critical Innate Pharma SA
Publication of AU2019270277A1 publication Critical patent/AU2019270277A1/en
Application granted granted Critical
Publication of AU2019270277B2 publication Critical patent/AU2019270277B2/en
Publication of AU2019270277B9 publication Critical patent/AU2019270277B9/en
Priority to AU2025200275A priority Critical patent/AU2025200275A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019270277A 2018-05-15 2019-05-14 Treatment of cancer Active AU2019270277B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200275A AU2025200275A1 (en) 2018-05-15 2025-01-14 Treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671521P 2018-05-15 2018-05-15
US62/671,521 2018-05-15
PCT/EP2019/062305 WO2019219658A1 (en) 2018-05-15 2019-05-14 Treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200275A Division AU2025200275A1 (en) 2018-05-15 2025-01-14 Treatment of cancer

Publications (3)

Publication Number Publication Date
AU2019270277A1 AU2019270277A1 (en) 2021-01-07
AU2019270277B2 AU2019270277B2 (en) 2024-11-21
AU2019270277B9 true AU2019270277B9 (en) 2024-12-05

Family

ID=66752041

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019270277A Active AU2019270277B9 (en) 2018-05-15 2019-05-14 Treatment of cancer
AU2025200275A Pending AU2025200275A1 (en) 2018-05-15 2025-01-14 Treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200275A Pending AU2025200275A1 (en) 2018-05-15 2025-01-14 Treatment of cancer

Country Status (13)

Country Link
US (1) US12209126B2 (https=)
EP (1) EP3793607A1 (https=)
JP (2) JP7531404B2 (https=)
KR (1) KR102885515B1 (https=)
CN (1) CN112203691A (https=)
AU (2) AU2019270277B9 (https=)
CA (1) CA3099820A1 (https=)
EA (1) EA202092696A1 (https=)
IL (1) IL278618B2 (https=)
MA (1) MA52627A (https=)
SG (1) SG11202011117VA (https=)
TW (1) TW202011989A (https=)
WO (1) WO2019219658A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
WO2019175182A1 (en) 2018-03-13 2019-09-19 Innate Pharma Treatment of head and neck cancer
CN113583127A (zh) * 2020-04-30 2021-11-02 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
CN115516086A (zh) * 2020-05-13 2022-12-23 南京传奇生物科技有限公司 类猿icp47及变体减少同种异体细胞宿主排斥的组合物及方法
WO2023284874A1 (zh) * 2021-07-16 2023-01-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
PE20241475A1 (es) * 2021-10-04 2024-07-17 Servier Lab Terapia del cancer dirigida a nkg2a
JP2025500845A (ja) * 2021-12-14 2025-01-15 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｃｄ９４／ｎｋｇ２ａヘテロ二量体ポリペプチドに結合する分子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
PT1831258E (pt) 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
KR20100110864A (ko) 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
KR102047248B1 (ko) 2011-06-17 2019-11-21 노보 노르디스크 에이/에스 침식성 세포의 선택적 제거
RU2017105425A (ru) * 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
AU2015316991B2 (en) 2014-09-16 2021-04-01 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
US10329348B2 (en) 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
SI3405495T1 (sl) 2016-01-21 2021-08-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih
WO2019175182A1 (en) 2018-03-13 2019-09-19 Innate Pharma Treatment of head and neck cancer

Also Published As

Publication number Publication date
CA3099820A1 (en) 2019-11-21
SG11202011117VA (en) 2020-12-30
IL278618A (https=) 2021-01-31
CN112203691A (zh) 2021-01-08
TW202011989A (zh) 2020-04-01
MA52627A (fr) 2021-03-24
WO2019219658A1 (en) 2019-11-21
KR20210010486A (ko) 2021-01-27
JP2024102055A (ja) 2024-07-30
AU2025200275A1 (en) 2025-01-30
KR102885515B1 (ko) 2025-11-12
US12209126B2 (en) 2025-01-28
IL278618B2 (en) 2025-11-01
EP3793607A1 (en) 2021-03-24
AU2019270277B2 (en) 2024-11-21
EA202092696A1 (ru) 2021-04-05
JP7531404B2 (ja) 2024-08-09
IL278618B1 (en) 2025-07-01
JP2021523170A (ja) 2021-09-02
US20210253694A1 (en) 2021-08-19
AU2019270277A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
AU2019270277B9 (en) Treatment of cancer
US20230303691A1 (en) Neutralization of inhibitory pathways in lymphocytes
CN112004828B (zh) 头颈癌的治疗
EA049949B1 (ru) Лечение рака
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes
HK40058058A (en) Neutralization of inhibitory pathways in lymphocytes
NZ729207B2 (en) Neutralization of inhibitory pathways in lymphocytes

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)